Please try another search
For the fiscal year ended 31 March 2022, Nichi-iko Pharmaceutical Co., Ltd. revenues decreased 5% to Y179.06B. Net loss applicable to common stockholders increased from Y4.18B to Y104.87B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Total SG&A Expense increase of 3% to Y27.88B (expense), Equity in Loss of Affiliates decrease of 53% to Y203M (income).
Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
---|---|---|---|---|
Total Revenue | 47462 | 44188 | 47062 | 44168 |
Gross Profit | -1957 | -10829 | 3001 | -3028 |
Operating Income | -13397 | -51294 | -6549 | -12772 |
Net Income | -16341 | -50617 | -4200 | -89280 |
Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
---|---|---|---|---|
Total Assets | 234621 | 246558 | 266215 | 260559 |
Total Liabilities | 286722 | 282184 | 253767 | 246786 |
Total Equity | -52101 | -35626 | 12448 | 13773 |
Period Ending: | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -1074 | -18735 | -15889 | 645 |
Cash From Investing Activities | -1943 | -1555 | -884 | -39 |
Cash From Financing Activities | 2420 | 23158 | 10941 | -2546 |
Net Change in Cash | -647 | 3002 | -5318 | -1447 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review